🌲 Company hike in the Rheinland-Pfalz! 🌲 🥾🍇 Last week, our team went on an exciting hiking trip to the beautiful Southern Wine Route and explored the trails above Rhodt all the way to the impressive ruins. It was the perfect way to connect with nature, recharge, and strengthen the bonds of our hard-working team—dedicated to providing the world with sustainable antibacterial solutions. 🧪 #TeamBuilding #HikingAdventure #Pfalz #NatureAndWork
MEDEA Biopharma
Biotechnologieforschung
Ludwigshafen, Rhineland-Palatinate 973 Follower:innen
Developing new generation of sustainable antibacterial solutions.
Info
Medea Biopharma GmbH, a German biotech company based in Ludwigshafen, Germany, was co-founded by Rüdiger Trojok, Dr. Elene Kakabadze, and Giorgi Khubua. Medea Biopharma GmbH specializes in the development of a new generation of sustainable and eco-friendly antibacterial solutions based on bacteriophages (phages), designed to solve the global crisis of antimicrobial resistance. Phages are natural bacterial killers, which are highly specific and without side effects. These innovative alternatives aim to replace conventional chemical antibiotics, copper-based solutions, and harmful pesticides, offering effective and environmentally responsible ways to combat harmful bacteria across diverse sectors, including human health, animal well-being, and agriculture.
- Website
-
www.medea-bio.com
Externer Link zu MEDEA Biopharma
- Branche
- Biotechnologieforschung
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Ludwigshafen, Rhineland-Palatinate
- Art
- Privatunternehmen
- Gegründet
- 2023
Orte
-
Primär
Donnersbergweg 1
Ludwigshafen, Rhineland-Palatinate 67059, DE
Beschäftigte von MEDEA Biopharma
Updates
-
🌟 MEDEA Biopharma was part of #Curious2024 Future Insight Conference! Organized by Future Insight e.V. and launched by Ulrich Betz from Merck Group, the event focused on breakthrough science topics various areas. 🌍 With 1600 on-site and over 3700 total attendees from 40+ countries, 130 speakers including Ugur Sahin from BioNTech SE and 7 Nobel laureates, the conference offered deep insights about scientific achievements and challenges, among others the antimicrobial resistance, bacteriophages and their potential. Big thanks to the Ministerium für Wirtschaft, Verkehr, Landwirtschaft und Weinbau Rheinland-Pfalz for inviting MEDEA Biopharma! #Bacteriophages #FutureScience #Breakthroughs #Sustainability
-
Excited to share highlights from our recent days in Lausanne, as participants of the MassChallenge Switzerland 2024 cohort, where MEDEA Biopharma won the Bühler Group's competition! MEDEA Biopharma was selected among the elite 8% of startups chosen from a worldwide applicant pool. This opportunity enabled us to explore collaborations and the opportunities of our next generation sustainable antibacterial substances with corporate partners such as Nestlé, dsm-firmenich, Bühler Group, Südzucker, Omyam, Givaudan and many more. A big thank you to the whole the MassChallenge Switzerland team! Matthew Lashmar, Nicolas Meneses, Giorgia Scetta, PhD, Marco Iotti, Elodie Waquet, Hendrik Marcel Dik, Augustin Woronoff, and all the contributors. #MassChallenge #Startup #Medea #bacteriophages #sustainability
-
+2
-
Hanno Charisius' recent article in Süddeutsche Zeitung highlights the growing importance of bacteriophages in combating antibiotic resistance of bacteria. Sharing such information helps to raise awareness for urgent need of new solutions and large potential of bacteriophages. #AntibioticResistance #Bacteriophages #InnovativeTherapies #HealthcareInnovation #Biotechnology
-
🚀 Exciting News! MEDEA Biopharma has been selected as finalists in the prestigious MassChallenge Switzerland 2024! This recognition places us among the world’s most innovative and impactful young enterprises. 💡🧬 Being part of this exclusive program offers us new opportunities for growth, mentorship, and global networking. We look forward to leveraging this platform to drive our mission forward. 🌐🤝
-
🚀 Exciting News! MEDEA Biopharma has been selected as finalists in the prestigious MassChallenge Switzerland 2024! This recognition places us among the world’s most innovative and impactful young enterprises. 💡🧬 Being part of this exclusive program offers us new opportunities for growth, mentorship, and global networking. We look forward to leveraging this platform to drive our mission forward. 🌐🤝
🎉 We’re excited to announce our 2024 Cohort! 🎉
MassChallenge Switzerland Announces Its 2024 Early-Stage Accelerator Cohort
MassChallenge Switzerland auf LinkedIn
-
🚀 MEDEA Biopharma is attending 𝐏𝐞𝐭𝐜𝐚𝐫𝐞 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 2024, 4-5 June in Berlin! 🐾 🧬 Looking forward to meeting with industry stakeholders from across Europe to dig into the latest trends and innovations driving the petcare industry forward! 🚀 Join us in Berlin: https://hubs.ly/Q027bQRG0 #PCI2024 #petcareinnovation #petcare #bacteriophages #phages #biotech
-
🚨 The World Health Organization warns of rising antibiotic resistance, posing a significant threat to global health and updates list of drug-resistant bacteria most threatening to human health❗ With 𝐚𝐧𝐭𝐢𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐧𝐠 𝐭𝐨 𝐚𝐫𝐨𝐮𝐧𝐝 𝐟𝐢𝐯𝐞 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐝𝐞𝐚𝐭𝐡𝐬 𝐚𝐧𝐧𝐮𝐚𝐥𝐥𝐲, it's critical to invest in new treatments. At MEDEA Biopharma, we’re pioneering sustainable 𝐩𝐡𝐚𝐠𝐞-𝐛𝐚𝐬𝐞𝐝 𝐚𝐧𝐭𝐢𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥𝐬 to tackle this crisis and to target resistant bacteria. Join us in the fight against antimicrobial resistance and help secure a healthier future. 🌍🔬 #Healthcare #Biotech #Innovation #AMR #PhageTherapy #Medea
WHO updates list of drug-resistant bacteria most threatening to human health
who.int
-
🔬 Exciting news and great progress for phage therapy! 🌐 The 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐩𝐨𝐞𝐢𝐚 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 (𝐄𝐏𝐂) has adopted the first 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐩𝐨𝐞𝐢𝐚 𝐭𝐞𝐱𝐭 on phage therapy medicinal products. This significant advancement establishes a standardized framework of requirements for the production and control of phage therapy products, a crucial step forward for the field! At MEDEA Biopharma, the new chapter in the 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐩𝐨𝐞𝐢𝐚 aligns with our commitment to developing safe and effective antibacterial solutions as antimicrobial resistance continues to be a significant global health threat. #PhageTherapy #Biotech #Innovation #PublicHealth #EDQM
New general chapter on Phage therapy medicinal products (5.31) adopted and pre-published on the EDQM website - European Directorate for the Quality of Medicines & HealthCare - EDQM
edqm.eu
-
📰 Exciting article on Forbes! 💡 Rob Kniaz, Managing Partner at Hoxton Ventures, highlights the immense potential of phages to combat antibiotic resistance and to revolutionize both animal and human health industries. 🧬 At MEDEA Biopharma, we're developing cutting-edge sustainable phage-based antibacterial solutions. 🚀 #BiotechInnovation #PhageTherapy #HealthcareRevolution
Phages, The Next Trillion Dollar Idea In Biotech
forbes.com
Ähnliche Seiten
Finanzierung
Letzte Runde
Unterstützung ohne FremdkapitalInvestor:innen
MassChallenge Switzerland